

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

VOLUNTARY ANNOUNCEMENT COMMENCEMENT OF NEW BUSINESS ACTIVITY

This announcement is made by Huakang Biomedical Holdings Company Limited (“**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company (“**Shareholders**”) and potential investors informed of the latest business development of the Group. The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to announce that the Group intends to commence trading business of enzyme-based products of Bestzym & Bestlife Group (China) Co., Limited (酶好生活集團(中國)有限公司) which involves the operation of an online sales platform and the business-to-business product trading (“**New Business Activity**”).

As at the date hereof, the Group is principally engaged in research and development, manufacture, marketing and sales of IVD reagents and auxiliary reproductive supplies and equipment in the PRC. The Board is actively exploring new business opportunities in order to bring a higher return to the Shareholders. Taking into account the continuing growth potential of the domestic consumption of enzyme-based products and the e-commerce industry in China in recent years, the Directors are of the view that the commencement of the New Business Activity will be a good opportunity for the Group to diversify its income streams which may ultimately enhance the financial performance of the Group. The Board is of the view that the commencement of the New Business Activity will be in the interest of the Company and the Shareholders as a whole.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 22 July 2024

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Ms. Chow Ching Man.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.